Figures computed from official regulatory filings — .
Analysttarget 9.1 USD (+127%) · consensus 4.64/5 · 10 buy · 1 hold · 0 sell
Ownershipinsiders 9.74% · institutions 98.39% · short 26.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Rezolute, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
150 buys7 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Karnawat Sunil Ratilal | Other | $10.2K | SEC |
| Evans Darontrack record | Other | $15.3K | SEC |
| Elam Nevan C | Other | $39.9K | SEC |
| ROBERTS BRIAN KENNETHtrack record | Other | $15.3K | SEC |
| Evans Darontrack record | Buy | $28.5K | conv 31 | SEC |
| ROBERTS BRIAN KENNETHtrack record | Other | $34.2K | SEC |
| Elam Nevan C | Other | $82.6K | Unusual size | SEC |
| Evans Darontrack record | Other | $34.2K | Unusual size | SEC |
| ROBERTS BRIAN KENNETHtrack record | Buy | $47.6K | conv 63ClusterUnusual size | SEC |
| Hogenhuis Wladimirtrack record | Buy | $9.5K | conv 45Cluster | SEC |
| Evans Darontrack record | Buy | $70.8K | conv 61Cluster | SEC |
| Evans Darontrack record | Buy | $4.5K | conv 63Cluster | SEC |
| Evans Darontrack record | Buy | $4.5K | conv 63Cluster | SEC |
| Karnawat Sunil Ratilal | Buy | $19.4K | conv 71ClusterFirst in 12mo | SEC |
| Karnawat Sunil Ratilal | Buy | $160 | conv 64ClusterFirst in 12mo | SEC |
| Elam Nevan C | Buy | $50.9K | conv 41Cluster | SEC |
| KREHER NERISSA | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Elam Nevan C | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Harris Erik | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Karnawat Sunil Ratilal | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hogenhuis Wladimirtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FAUCHET PHILIPPE | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FAUCHET PHILIPPE | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Labrucherie Gil Mtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Evans Darontrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |